Cancer test kit NEUROPRO™

oncologyfor precision medicinefor MGMT Gene Methylation

Primary central nervous system (CNS) tumors are a group of tumor types originating from the brain or spinal cord tissue, and can be differentiated from metastatic brain tumors that spread to the brain from a tumor developed in another part of the body. Although certain genetic syndromes may increase the risk of developing CNS tumors, the causes of most adult primary CNS tumors are still unknown. Targets 494 key genes in central nervous system tumors  Detection of single nucleotide variants (SNVs), small insertions and deletions (indels), gene fusions, copy number variations (CNVs), chromosomal aberration, and O(6)- methylguanine-DNA methyltransferase (MGMT) promoter methylation to characterize central nervous system (CNS) tumor subtypes and guide personalized treatment  Comprehensive evaluation of genes recommended in WHO/NCCN/CSCO guidelines to reveal clinical benefits  Assess targetable gene alterations to match patients for targeted therapy and immunotherapy  Hereditary cancer risk assessment for early intervention Coverage of prognosis-related genes to direct treatment decision making WHO IS IT FOR Newly diagnosed patients Patients with an unclear CNS diagnosis Patients seeking personalized treatment plans Patients that experience ineffective conventional treatments SAMPLE TYPES* SAMPLE TYPES* Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy *MGMT and 1p/19q detection only apply to tumor tissue samples Contact us today to learn more about NEUROPRO™